Cyrus Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-12-2024
- Paid Up Capital ₹ 0.50 M
as on 17-12-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 639.55%
(FY 2023)
- Profit -133.15%
(FY 2023)
- Ebitda -132.58%
(FY 2023)
- Net Worth -237.19%
(FY 2023)
- Total Assets 66.76%
(FY 2023)
About Cyrus Remedies
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rachana Shah and Mehul Shah serve as directors at the Company.
- CIN/LLPIN
U24110MH2021PTC365048
- Company No.
365048
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Cyrus Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rachana Shah  | Additional Director | 15-Apr-2024 | Current |
| Mehul Shah | Director | 02-Aug-2021 | Current |
Financial Performance of Cyrus Remedies.
Cyrus Remedies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 639.55% increase. The company also saw a substantial fall in profitability, with a 133.15% decrease in profit. The company's net worth observed a substantial decline by a decrease of 237.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cyrus Remedies?
Unlock access to Cyrus Remedies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Alchem Biozyme Research And Development Private LimitedActive 2 years 6 monthsRachana Shah and Mehul Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cyrus Remedies?
Cyrus Remedies has a workforce of 127 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cyrus Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cyrus Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
